Medinol Ltd. – Trademark Portfolio

Entity Type: 03

Medinol Ltd. holds 89 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 89 filings in this category. The portfolio also extends into Class 37 (Building & Construction) across 2 Nice Classification classes. Currently, 6 trademarks are registered and 1 is pending. Notable registered marks include NIR, ELUNIR, MEDINOL, CHAMPIONIR, and ELUNIR-PERL. The owner is based in Tel Aviv 61581.

Kiryat Atidim, Building 7

Tel Aviv 61581 , IL

89 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 4 (89 results)

Trademark Classifications

Medinol Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (89 filings)

Surgical, medical, dental and veterinary apparatus and instruments

37
Building & Construction (1 filing)

Building construction; repair; installation services

Frequently Asked Questions

How many trademarks does Medinol Ltd. have?

Medinol Ltd. has 89 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 pending, 74 abandoned, 8 cancelled.

What trademark classes does Medinol Ltd. file in?

Medinol Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 37 (Building & Construction). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Medinol Ltd.'s most well-known trademarks?

Medinol Ltd.'s registered trademark portfolio includes well-known marks such as NIR, ELUNIR, MEDINOL, CHAMPIONIR, and ELUNIR-PERL. These are among 6 currently registered trademarks in the portfolio.

What is Medinol Ltd.'s trademark registration success rate?

Medinol Ltd. has a 7% trademark registration rate, with 6 out of 88 resolved applications resulting in successful registration. Currently, 1 application is pending review.